According to the business intelligence report titled ‘GLOBAL Contraceptive Market 2019-2027’, available with Market Study Report, global contraceptive market is speculated to grow at an annual rate of 6.93% between 2019-2027.
 

Favorable government initiatives, growing awareness about risk of acquiring STIs, rising disposable incomes and technological developments are key factors propelling global contraceptive market growth. Moreover, rising consumption of oral contraceptives to prevent unwanted pregnancies and growing cognizance regarding the benefits of the product are likely to stimulate industry expansion.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2486933/
 

On the other hand, limited access to contraceptives, rising concerns regarding the side effects associated with the product, and lack of awareness could potentially act as a challenge in global contraceptive industry proliferation.
 

Regionally speaking, North America is projected to hold majority of the worldwide contraceptive industry share by 2027 owing to growing number of unwanted pregnancies in the region.
 

Meanwhile, Europe contraceptive market size is speculated to grow rapidly through 2027 primarily due to the launch of new products and several initiatives taken by government to educate people about contraceptives.
 

Asia-Pacific too is likely to generate lucrative returns for the industry participants in the ensuing years, owing to growing number of STIs and rising importance regarding the use of contraceptives.
 

Key players influencing global contraceptive market dynamics are Allergan Inc., Melbea, Pfizer Inc., Okamoto Industries Inc., Reckitt Benckiser Group plc, Ocon Medical Ltd., Teva Pharmaceutical Industries Ltd., Pregna International Limited, Cooper Surgical Inc., Bayer AG, Afaxys Inc., Mayer Laboratories Inc., Church & Dwight Co. Inc., Apothecus Pharmaceutical Corporation, Merck & Co. Inc., SMB Corporation of India and Agile Therapeutics Inc.